artemether-lumefantrine

artemether-lumefantrine. It is a fixed-dose combination antimalarial medication used primarily for the treatment of uncomplicated falciparum malaria. The therapy combines two agents, artemether and lumefantrine, which work synergistically to rapidly reduce the number of parasites and prevent recrudescence. It is on the World Health Organization's List of Essential Medicines and is a cornerstone of artemisinin-based combination therapy (ACT) recommended globally.

Medical uses

It is indicated for the acute treatment of uncomplicated malaria caused by Plasmodium falciparum, including in regions with known resistance to older drugs like chloroquine and sulfadoxine/pyrimethamine. Its use is guided by treatment protocols from the World Health Organization and national bodies such as the Centers for Disease Control and Prevention. It is not used for the treatment of severe malaria, which requires parenteral therapy such as artesunate, nor for prophylaxis. Efficacy is high in areas like sub-Saharan Africa and Southeast Asia, though monitoring for artemisinin resistance is conducted by networks like the WorldWide Antimalarial Resistance Network.

Adverse effects

Common adverse effects are generally mild and include headache, dizziness, anorexia, and arthralgia. Electrocardiography studies, particularly monitoring the QT interval, are considered due to a potential risk with lumefantrine, though significant cardiac events are rare. Other reported effects can involve the gastrointestinal tract, such as nausea and abdominal pain. Serious reactions are uncommon but can include severe allergic reactions or hematological abnormalities.

Pharmacology

The combination exploits distinct mechanisms of action for synergistic effect. Artemether, a derivative of artemisinin isolated from Artemisia annua, generates reactive oxygen species that damage parasite membranes and proteins. Lumefantrine, developed by the Academy of Military Medical Sciences in China, inhibits the formation of hemozoin by binding to heme, a process critical for parasite detoxification. Pharmacokinetically, artemether is rapidly absorbed and converted to its active metabolite dihydroartemisinin, while lumefantrine is highly lipophilic, with absorption enhanced by fatty food; this is why administration with food is critical.

History

The development originated from Chinese malaria research programs in the 1970s following the discovery of artemisinin by Tu Youyou and her team, for which Tu was awarded the Nobel Prize in Physiology or Medicine. Lumefantrine (originally benflumetol) was synthesized in the 1970s. The fixed-dose combination was later developed through collaboration between Novartis and Chinese institutions. It received prequalification from the World Health Organization in 2002, facilitating its widespread adoption. Its rollout was a major component of global health initiatives supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the President's Malaria Initiative.

Society and culture

It is marketed under brand names including Coartem and Riamet. A significant public health achievement was the development of a dispersible tablet formulation for children, pioneered by Novartis and Medicines for Malaria Venture. Its cost and availability have been shaped by agreements with procurement agencies like the Global Fund and UNITAID. The therapy features in treatment guidelines from Médecins Sans Frontières and national programs across Africa. Cultural considerations include ensuring adherence to the multi-dose regimen and addressing community awareness through organizations like the Roll Back Malaria Partnership.

Category:Antimalarial agents Category:World Health Organization essential medicines Category:Combination drugs